Zymeworks shares gain on promising data for cancer drug in development with Jazz Pharmaceuticals

Shares of Zymeworks Inc. ZYME rallied 14% in premarket trading on Thursday after the company and Jazz Pharmaceuticals Inc. JAZZ said their experimental cancer drug had an overall survival rate of 84% in patients being treated for a type of metastatic gastroesophageal adenocarcinoma after 18 months. The companies are testing zanidatamab in combination with chemotherapy as a first-line treatment in an open-label Phase 2 clinical trial.

... Shares of Zymeworks Inc. ZYME rallied 14% in premarket trading on Thursday after the company and Jazz Pharmaceuticals Inc. JAZZ said their experimental cancer drug had an overall survival rate of 84% in patients being treated for a type of metastatic gastroesophageal adenocarcinoma after 18 months. The companies are testing zanidatamab in combination with chemotherapy as a first-line treatment in an open-label Phase 2 clinical trial.

Business Business Latest News, Business Business Headlines

Similar News:You can also read news stories similar to this one that we have collected from other news sources.

Japan Inc is finally giving raises, just not to everyoneJapan's top companies are gearing up to offer their biggest wage increases in decades, but there's no way Hideki Kawada can afford raises for the 18 employees at his printing firm. Japan have quailty old fashion jeans production. Expensive brand It’s hard to give raises without improvements in productivity. Scant evidence of that in Japan (for a long time, actually).
Source: Reuters - 🏆 2. / 97 Read more »